Cargando…
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time...
Autores principales: | Assaf, Zoe June F., Zou, Wei, Fine, Alexander D., Socinski, Mark A., Young, Amanda, Lipson, Doron, Freidin, Jonathan F., Kennedy, Mark, Polisecki, Eliana, Nishio, Makoto, Fabrizio, David, Oxnard, Geoffrey R., Cummings, Craig, Rode, Anja, Reck, Martin, Patil, Namrata S., Lee, Mark, Shames, David S., Schulze, Katja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115641/ https://www.ncbi.nlm.nih.gov/pubmed/36928816 http://dx.doi.org/10.1038/s41591-023-02226-6 |
Ejemplares similares
-
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
por: West, Howard Jack, et al.
Publicado: (2022) -
Molecular determinants of response to PD-L1 blockade across tumor types
por: Banchereau, Romain, et al.
Publicado: (2021) -
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023) -
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
por: Bhattacharya, Saveri, et al.
Publicado: (2015) -
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials
por: Socinski, Mark A., et al.
Publicado: (2023)